Marker Therapeutics, Inc (MRKR)

Etorro trading 970x250
Marker Therapeutics, Inc (MRKR) Logo

About Marker Therapeutics, Inc

Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company’s MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial for the treatment of breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. Marker Therapeutics, Inc. is headquartered in Houston, Texas. Address: Phoenix Tower, Houston, TX, United States, 77027

Marker Therapeutics, Inc News and around…

Latest news about Marker Therapeutics, Inc (MRKR) common stock and company :

12 Health Care Stocks Moving In Thursday's After-Market Session
18 Nov, 2021 FinancialContent

Gainers NeuroOne Medical Tech (NASDAQ:NMTC) stock moved upwards by 6.47% to $2.63 during Thursday's after-market session. The ...

Marker Therapeutics Announces that Data from Investigator-Sponsored Phase 1 Study With its MultiTAA-Specific T Cells to be Presented at the 2021 American Society of Hematology Annual Meeting
18 Nov, 2021 Yahoo! Finance

Marker Therapeutics, Inc. (NASDAQ: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that data from a Phase 1 study investigating its MultiTAA-specific T cells were selected for oral presentation at the 2021 American Society of Hematology (ASH) Annual Meeting. The results will be reviewed by investigators at the Baylor College

Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results
10 Nov, 2021 Yahoo! Finance

Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the third quarter ended September 30, 2021.

Bullish insiders bet US$1.3m on Marker Therapeutics, Inc. (NASDAQ:MRKR)
08 Oct, 2021 Yahoo! Finance

Multiple insiders secured a larger position in Marker Therapeutics, Inc. ( NASDAQ:MRKR ) shares over the last 12...

12 Health Care Stocks Moving In Wednesday's After-Market Session
08 Sep, 2021 FinancialContent

Gainers Cardiff Oncology (NASDAQ:CRDF) shares increased by 24.68% to $8.79 during Wednesday's after-market session. ...

Marker Therapeutics to Present at Three Upcoming September Investor Conferences
07 Sep, 2021 Yahoo! Finance

Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the Company will present at three upcoming virtual investor conferences in September.

58 Biggest Movers From Friday
23 Aug, 2021 FinancialContent

Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares climbed 204.1% to close at $19.16 on Friday. Regencell ...

38 Stocks Moving In Friday's Mid-Day Session
20 Aug, 2021 FinancialContent

Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares climbed 45.8% to $6.27 after the company presented data from ongoing studies of ...

11 Health Care Stocks Moving In Friday's Pre-Market Session
20 Aug, 2021 FinancialContent

Gainers Geovax Labs (NASDAQ:GOVX) stock moved upwards by 74.65% to $7.51. The market value of their outstanding shares ...

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
20 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
20 Aug, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! The week's almost done with just one more day of trading so let's start it with the biggest pre-market stock movers for Friday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

22 Stocks Moving in Friday's Pre-Market Session
20 Aug, 2021 FinancialContent

Gainers GeoVax Labs, Inc.. (NASDAQ: GOVX) shares rose 72.1% to $7.40 in pre-market trading after the company announced it ...

Marker Therapeutics Secures $13.1M Grant To Support MultiTAA Cell Therapy Trial
20 Aug, 2021 FinancialContent

Marker Therapeutics Inc(NASDAQ: MRKR) received notice of a Product Development Researchaward of approximately $13.1 ...

Marker Therapeutics Awarded $13.1 Million Grant from the Cancer Prevention and Research Institute of Texas
19 Aug, 2021 Yahoo! Finance

Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the Company received notice of a Product Development Research award totaling approximately $13.1 million from the Cancer Prevention and Research Institute of Texas (CPRIT) to support the Company's Phase 2 clinical trial of its lead MultiTAA

Interesting MRKR Call Options For September 17th
12 Aug, 2021 FinancialContent

Investors in Marker Therapeutics Inc (MRKR) saw new options become available this week, for the September 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MRKR options chain for the new September 17th contracts and identified the following call contract of particular interest.

Marker Therapeutics Reports Second Quarter 2021 Operating and Financial Results
10 Aug, 2021 Yahoo! Finance

Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the second quarter ended June 30, 2021.

Is Marker Therapeutics, Inc.'s (NASDAQ:MRKR) Shareholder Ownership Skewed Towards Insiders?
09 Aug, 2021 Yahoo! Finance

Every investor in Marker Therapeutics, Inc. ( NASDAQ:MRKR ) should be aware of the most powerful shareholder groups...

The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
29 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Marker Therapeutics Announces Opening of New cGMP Manufacturing Facility
28 Jul, 2021 Yahoo! Finance

Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the Company's new cGMP manufacturing facility in Houston, TX, located near the George Bush Intercontinental Airport, is fully operational. The facility will manufacture Marker's MultiTAA-specific T cell products for the Company's Phase 2 ac

Analysts Expect VTWV To Hit $157
08 Jul, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Value ETF (VTWV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $156.76 per unit.

Marker Therapeutics Announces Completion of Safety Lead-In Portion of Phase 2 Study in Post-Transplant AML
06 Jul, 2021 Yahoo! Finance

Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced completion of the six-patient safety lead-in portion of the Company's Phase 2 trial of MT-401, its lead MultiTAA-specific T cell product candidate, for the treatment of post-transplant acute myeloid leukemia (AML).

Marker Therapeutics, Inc. (MRKR): Are Hedge Funds Right About This Stock?
29 Jun, 2021 Yahoo! Finance

The Insider Monkey team has completed processing the quarterly 13F filings for the March quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]

Marker Therapeutics to Present at the Virtual Raymond James Human Health Innovation Conference
16 Jun, 2021 Yahoo! Finance

Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its Chief Financial Officer, Anthony H. Kim, will present at the upcoming virtual Raymond James Human Health Innovation Conference on Monday, June 21, 2021 at 9:20 a.m. ET.

5 Penny Stocks Analysts Say To Buy With Targets Up To 219% Right Now
23 May, 2021 FinancialContent
Top Penny Stocks to Buy Today? Here’s 3 to Watch in 2021
21 May, 2021 FinancialContent
Increased R&D Activities Have Fueled Growth and Promise for Pancreatic Cancer Treatment
20 May, 2021 FinancialContent
Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation
20 May, 2021 Yahoo! Finance

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

We Did The Math IWV Can Go To $271
13 May, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Russell 3000 ETF (IWV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $271.32 per unit.

Marker Therapeutics Reports First Quarter 2021 Operating and Financial Results
12 May, 2021 Yahoo! Finance

Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the first quarter ended March 31, 2021.

Marker Therapeutics, Inc. to Host Earnings Call
12 May, 2021 Yahoo! Finance

NEW YORK, NY / ACCESSWIRE / May 12, 2021 / Marker Therapeutics, Inc. (NASDAQ:MRKR) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 12, 2021 at 5:00 PM Eastern Time.

Marker Therapeutics, Inc (MRKR) is a NASDAQ Common Stock listed in , ,

970x250